Literature DB >> 20807590

Modulation of autoimmunity with artificial peptides.

Antonio La Cava1.   

Abstract

The loss of immune tolerance to self antigens leads to the development of autoimmune responses. Since self antigens are often multiple and/or their sequences may be known, one approach to restore immune tolerance uses synthetic artificial peptides that interfere or compete with self peptides in the networks of cellular interactions that drive the autoimmune process. This review describes the rationale behind the use of artificial peptides in autoimmunity and their mechanisms of action. Examples of use of artificial peptides in preclinical studies and in the management of human autoimmune diseases are provided.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20807590      PMCID: PMC2975760          DOI: 10.1016/j.autrev.2010.08.017

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  34 in total

1.  Tolerogenic treatment of lupus mice with consensus peptide induces Foxp3-expressing, apoptosis-resistant, TGFbeta-secreting CD8+ T cell suppressors.

Authors:  Bevra H Hahn; Ram Pyare Singh; Antonio La Cava; Fanny M Ebling
Journal:  J Immunol       Date:  2005-12-01       Impact factor: 5.422

2.  Exploiting T cell crosstalk as a vaccination strategy for rheumatoid arthritis.

Authors:  Berent Prakken; Salvatore Albani
Journal:  Arthritis Rheum       Date:  2007-02

3.  Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide.

Authors:  D Teitelbaum; A Meshorer; T Hirshfeld; R Arnon; M Sela
Journal:  Eur J Immunol       Date:  1971-08       Impact factor: 5.532

4.  Treatment with a consensus peptide based on amino acid sequences in autoantibodies prevents T cell activation by autoantigens and delays disease onset in murine lupus.

Authors:  B H Hahn; R R Singh; W K Wong; B P Tsao; K Bulpitt; F M Ebling
Journal:  Arthritis Rheum       Date:  2001-02

5.  Multiple sclerosis: comparison of copolymer-1- reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells.

Authors:  O Neuhaus; C Farina; A Yassouridis; H Wiendl; F Then Bergh; T Dose; H Wekerle; R Hohlfeld
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-20       Impact factor: 11.205

Review 6.  Potential for anti-DNA immunoglobulin peptide therapy in systemic lupus erythematosus.

Authors:  Noriko Iikuni; Bevra H Hahn; Antonio La Cava
Journal:  Expert Opin Biol Ther       Date:  2009-02       Impact factor: 4.388

7.  Ig-reactive CD4+CD25+ T cells from tolerized (New Zealand Black x New Zealand White)F1 mice suppress in vitro production of antibodies to DNA.

Authors:  Antonio La Cava; Fanny M Ebling; Bevra H Hahn
Journal:  J Immunol       Date:  2004-09-01       Impact factor: 5.422

8.  Selective silencing of DNA-specific B lymphocytes delays lupus activity in MRL/lpr mice.

Authors:  Andrey I Tchorbanov; Elisaveta N Voynova; Nikolina M Mihaylova; Todor A Todorov; Maria Nikolova; Vihra M Yomtova; Bor-Luen Chiang; Tchavdar L Vassilev
Journal:  Eur J Immunol       Date:  2007-12       Impact factor: 5.532

9.  Protection against renal disease in (NZB x NZW)F(1) lupus-prone mice after somatic B cell gene vaccination with anti-DNA immunoglobulin consensus peptide.

Authors:  Francesca Ferrera; Bevra H Hahn; Marta Rizzi; Marissa Anderson; John Fitzgerald; Enrico Millo; Francesco Indiveri; Fu-Dong Shi; Gilberto Filaci; Antonio La Cava
Journal:  Arthritis Rheum       Date:  2007-06

Review 10.  Therapeutic vaccines in autoimmunity.

Authors:  Michael Sela; Edna Mozes
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-12       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.